bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events Read more about bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy Read more about bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
bluebird bio Announces Receipt of Expected Notice from Nasdaq Read more about bluebird bio Announces Receipt of Expected Notice from Nasdaq
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance Read more about bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call Read more about bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital Read more about bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy Read more about bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
bluebird bio Fourth Quarter and 2023 Annual Results Conference Call Read more about bluebird bio Fourth Quarter and 2023 Annual Results Conference Call
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook Read more about bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook